**Analysis of complete response by MRI following neoadjuvant chemotherapy predicts pathological tumor responses differently for molecular subtypes of breast cancer**
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After the publication of the article, the authors noted that they had made an error regarding certain data in their manuscript. The error relates to the calculations made in [Table IV](#t4-ol-05-04-1433){ref-type="table"}.

On page 88 of our article, in the left-handed column, we identified an erroneous statistical result with respect to the percentages calculated in [Table IV](#t4-ol-05-04-1433){ref-type="table"}. Please see the corrected table below.

###### 

Presence or absence of residual DCIS and MRI diagnoses.

                   Residual DCIS (%)               
  ---------------- ------------------- ----------- ------------
  cCR              36 (36.7)           8 (8.2)     44 (44.9)
  Residual tumor   30 (30.6)           24 (24.5)   54 (55.1)
  Total            66 (67.3)           32 (32.7)   98 (100.0)

P=0.0058. cCR, clinical complete response; DCIS, ductal carcinoma *in situ*; MRI, magnetic resonance imaging.
